IGROV-1 displayed alterations in TP53, BRCA1/2, and ATM, which are characteristic of serous carcinomas, but also harbored mutations in CTNNB1, APC, KMT2D, and RB1, more typically observed in endometrioid ovarian cancers. Here, BRCA1 is linked to serous adenocarcinoma.